Actively Recruiting
Treatment of Hypertension During Sleep
Led by University of Vigo · Updated on 2024-12-06
5320
Participants Needed
9
Research Sites
726 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
On the basis of new evidence on the relationship between achieved office blood pressure (BP) measurements (OBPM) and the risk of cardiovascular disease (CVD) morbidity and mortality documented in the SPRINT trial, the recent 2017 guidelines of the American College of Cardiology (ACC) and the American Heart Association (AHA) have established lower values of 130/80 mmHg for clinic systolic BP (SBP)/diastolic BP (DBP) as new diagnostic thresholds for hypertension and therapeutic targets for treatment of all individuals aged ≥18 years regardless of age, sex, or concomitant complications including presence of diabetes, chronic kidney disease (CKD), or history of past CVD event. According to these guidelines, the new proposed ambulatory BP measurment (ABPM) thresholds for diagnosis of hypertension in adults are 130/80 and 110/65 mmHg for the awake and asleep SBP/DBP means, respectively. However, the ACC/AHA guidelines do not provide any scientific evidence documenting neither the equivalence between these ABPM thresholds and the 130/80 mmHg cut-off values for OBPM nor the potential improved CVD event-free survival time of the proposed more intensive control of ambulatory BP. Results derived from observational prospective studies consistently document that therapeutic BP targets in hypertensive individuals, i.e., persons at increased CVD risk, should be established in terms of proper control of asleep BP. To date, no prospective randomized study has ever before evaluated which should be the adequate therapeutic ABPM target for most effective reduction of CVD risk. Accordingly, the Tratamiento de Hipertensión Arterial Durante el Sueño study (THADEUS, i.e., Treatment of Hypertension During Sleep) has been designed to prospectively evaluate if "intensive control" of asleep SBP mean proposed by the new ACC/AHA guidelines (\<110 mmHg) in more effective than the so far its "conventional control" (\<120 mmHg) to reduce CVD morbidity and mortality in hypertensive individuals.
CONDITIONS
Official Title
Treatment of Hypertension During Sleep
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women aged �3E�3D18 years
- Sleep-time hypertension with asleep SBP mean �3E�3D120 mmHg at randomization
- Routine daytime activity and nighttime sleep
- Provided written informed consent to participate
You will not qualify if you...
- Pregnancy
- History of drug or alcohol abuse within the last two years
- Night or shift work employment
- Previous systemic autoimmune disease or AIDS
- Secondary hypertension causes such as coarctation of the aorta, hyperaldosteronism, renal artery stenosis, or pheochromocytoma
- Cardiovascular disorders including unstable angina, heart failure, life-threatening arrhythmia, atrial fibrillation, kidney failure, and severe retinopathy
- Any surgical or medical condition affecting drug metabolism or increasing study risk or likelihood of non-compliance
- History of malignancy or other severe life-threatening diseases within the past five years
- Inability to communicate or comply with study requirements
- Intolerance to ambulatory blood pressure monitoring
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 9 locations
1
Complexo Hospitalario Universitario de Ourense
Ourense, Orense, Spain, 32005
Actively Recruiting
2
CS A Estrada
A Estrada, Pontevedra, Spain, 26680
Actively Recruiting
3
CS Panxón
Nigrán, Pontevedra, Spain, 36340
Actively Recruiting
4
Centro de Salud de A Doblada
Vigo, Pontevedra, Spain, 36205
Actively Recruiting
5
Centro de Salud de Bembrive
Vigo, Pontevedra, Spain, 36214
Actively Recruiting
6
Centro de Salud de Sardoma
Vigo, Pontevedra, Spain, 36214
Actively Recruiting
7
CS Teis
Vigo, Pontevedra, Spain, 36216
Actively Recruiting
8
Bioengineering & Chronobilogy Labs., University of Vigo
Vigo, Pontevedra, Spain, 36310
Actively Recruiting
9
CS San Roque
Vilagarcía de Arousa, Pontevedra, Spain, 36600
Actively Recruiting
Research Team
R
Ramon C Hermida, PhD
CONTACT
J
José R Fernández, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here